Clinical Trial

The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels

Study acronym: Morbid Obesity
Completed
View on ClinicalTrials.gov →
Summary
Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, particularly in patients with Type-III obesity and above. Currently, the most commonly performed bariatric metabolic surgical procedures are Laparoscopic Sleeve Gastrectomy (LSG) and Roux-en-Y gastric bypass. Animal studies have shown that phoenixin (PNX) in the paraventricular, arcuate, and solitary tract nuclei contributes to regulating food intake, and its intracerebral administration in rats increased food intake. The aim of this study is to investigate whether PNX-14 levels change before and after LSG in patients undergoing the procedure for severe obesity, given the potential association of PNX-14 with obesity and insulin resistance through its influence on the appetite center in metabolism.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-26; most recent amendment 2026-01-10.
Status change: Active, Not Recruiting → Completed 2026-01-10
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-09-01
Trial Details
NCT Number NCT07004556
Lead Sponsor Kahramanmaras Sutcu Imam University
Conditions Obesity, Morbid, Obesity and Overweight
Enrollment 36 participants
Start Date 2025-07-01
Primary Completion 2025-11-01 (estimated)
Study Completion 2025-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-13